Arcus Biosciences, Inc. (RCUS)
NYSE: RCUS · Real-Time Price · USD
7.95
-0.55 (-6.47%)
Jun 27, 2025, 4:00 PM - Market closed
Arcus Biosciences Stock Forecast
Stock Price Forecast
The 10 analysts that cover Arcus Biosciences stock have a consensus rating of "Buy" and an average price target of $23.75, which forecasts a 198.74% increase in the stock price over the next year. The lowest target is $13 and the highest is $44.
Price Target: $23.75 (+198.74%)
Analyst Consensus: Buy
* Price targets were last updated on May 9, 2025.
Analyst Ratings
The average analyst rating for Arcus Biosciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
---|---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 3 | 3 | 2 |
Buy | 6 | 6 | 6 | 6 | 6 | 6 |
Hold | 2 | 1 | 1 | 1 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 12 | 11 | 11 | 10 | 11 | 10 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Morgan Stanley | Morgan Stanley | Buy Maintains $24 → $22 | Buy | Maintains | $24 → $22 | +176.73% | May 9, 2025 |
Goldman Sachs | Goldman Sachs | Hold Maintains $15 → $13 | Hold | Maintains | $15 → $13 | +63.52% | May 8, 2025 |
Wells Fargo | Wells Fargo | Buy Maintains $29 → $26 | Buy | Maintains | $29 → $26 | +227.04% | May 7, 2025 |
Barclays | Barclays | Buy Maintains $29 → $14 | Buy | Maintains | $29 → $14 | +76.10% | Apr 23, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $24 | Hold → Strong Buy | Upgrades | $24 | +201.89% | Feb 26, 2025 |
Financial Forecast
Revenue This Year
119.42M
from 258.00M
Decreased by -53.71%
Revenue Next Year
153.73M
from 119.42M
Increased by 28.73%
EPS This Year
-4.65
from -3.14
EPS Next Year
-4.65
from -4.65
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 210.0M | 297.9M | 389.0M | ||
Avg | 119.4M | 153.7M | 231.0M | ||
Low | 85.9M | 43.1M | 99.2M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -18.6% | 149.4% | 153.0% | ||
Avg | -53.7% | 28.7% | 50.3% | ||
Low | -66.7% | -63.9% | -35.5% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -4.01 | -3.01 | -3.40 | ||
Avg | -4.65 | -4.65 | -4.50 | ||
Low | -5.61 | -6.33 | -5.80 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.